Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease Jun Arai, Akinori Okumura, Satoshi Kimoto, Kazumasa Sakamoto, Tomoya Kitada, Rena Kitano, Tadahisa Inoue, Sayaka Nishimura, Noriko Inden, Yukiko Muraki, Naoya Kato, Kiyoaki Ito Hepatology International.2025; 19(4): 836. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, Chuthathip Kaeosri, Banthoon Sukphutanan, Yanfang Pang, Narathorn Kulthamrongsri, Methasit Jaisa-aad, Cheng Han Ng, Margaret Teng, Masahito Nakano, Asahiro Morishita, Naim Alkhouri, Ju Dong Yang, Metabolism.2024; 158: 155958. CrossRef
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(3): 577. CrossRef
Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy? Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su JGH Open.2024;[Epub] CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.
Citations
Citations to this article as recorded by
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma J. M. John Britto, T Beula Bell Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution Fu-Qun Wei, Pei-Shu Huang, Bing Zhang, Rui Guo, Yan Yuan, Jin Chen, Zheng-Yu Lin BMC Cancer.2025;[Epub] CrossRef
Celecoxib as a potential treatment for hepatocellular carcinoma in populations exposed to high PFAS levels Boshi Sun, Yuqiao Zhao, Shifeng Yang, Xiaodong Li, Nana Li, Yujie Wang, Qixiang Han, Xuyun Liu, Qiushi Tu, Jie Zheng, Xinyu Zhang Journal of Hazardous Materials.2025; 489: 137613. CrossRef
Reply: Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma Deok Hwa Seo, Pil Soo Sung Hepatology.2025; 81(4): E123. CrossRef
A Chemotherapy Response-Related Gene Signature and DNAJC8 as Key Mediators of Hepatocellular Carcinoma Progression and Drug Resistance Yan Ye, Yanmei Zeng, Shenggang Huang, Chunping Zhu, Qingshui Wang Journal of Hepatocellular Carcinoma.2025; Volume 12: 579. CrossRef
A nomogram based on PNI and preoperative TACE can predict overall survival in patients with larger than 2 cm HCC after hepatectomy Huizhi Zhang, Chunyu Zhang, Run Hu, Kai Lei, Xingxing Wang, Zuojin Liu Updates in Surgery.2025; 77(4): 1113. CrossRef
Hepatocellular Carcinoma: A Comprehensive Review of Pathophysiology, Risk Factors, Diagnosis and Treatment Strategies Vedika N. Dafe, Pooja R. Hatwar , Ravindra L. Bakal , Harshdeep V. Bindod Journal of Drug Delivery and Therapeutics.2025; 15(5): 159. CrossRef
A technological convergence in hepatobiliary oncology: Evolving roles of smart surgical systems Xuanci Bai, Runze Huang, Qinyu Liu, Xin Jin, Lu Wang, Wei Tang, Kenji Karako, Weiping Zhu BioScience Trends.2025; 19(4): 410. CrossRef
Metabolic dysfunction associated fatty liver disease and type 2 diabetes: pathophysiological links, epidemiological trends, and clinical implications Mohammad Sarif Mohiuddin, Noushin Tabassum Neha, Jawad Ul Karim Mahir, Fardin Al Fahad Shakib, Md. Ashraful Alam, Md. Wahiduzzaman, Rashu Barua, Shakila Jahan Shimu, Mahbubur Rahman, Md. Rafin Hossain, Mohammad Hossain Shariare, Mohammad Mohabbulla Mohib, Frontiers in Endocrinology.2025;[Epub] CrossRef
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepato Zha Peng, Yaqiong Wang, Boyu Chen, Zhuangrong Zhu, Chengyi He, Yang Wei, Hai Huang Frontiers in Oncology.2025;[Epub] CrossRef
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Gastro Hep Advances.2024; 3(4): 506. CrossRef
Impact of bile leak on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection Hidetoshi Gon, Shohei Komatsu, Hirotoshi Soyama, Motofumi Tanaka, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukum Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients Tianying Ren, Xu Hou, Xin Zhang, Dongliang Chen, Juan Li, Yingnan Zhu, Zhiheng Liu, Dawei Yang Heliyon.2023; 9(11): e21906. CrossRef
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study Jonathan Abdelmalak, Simone I. Strasser, Natalie Ngu, Claude Dennis, Marie Sinclair, Avik Majumdar, Kate Collins, Katherine Bateman, Anouk Dev, Joshua H. Abasszade, Zina Valaydon, Daniel Saitta, Kathryn Gazelakis, Susan Byers, Jacinta Holmes, Alexander J. Cancers.2023; 15(24): 5741. CrossRef
Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are effective and contribute to prolonged patient survival, their effects are unsatisfactory for some specific tumor conditions, such as macrovascular invasion. Hepatic arterial infusion chemotherapy (HAIC) is a traditional treatment for advanced HCC. As yet, there is no worldwide consensus recommending HAIC because no high-quality clinical trials have demonstrated its survival benefit. However, clinical evidence is gradually accumulating that shows its survival benefit, and it is recognized as an effective locoregional treatment for advanced HCC. Several HAIC regimens have been reported, including cisplatin monotherapy, cisplatin plus 5-fluorouracil (low-dose FP), lipiodol-suspended FP, and an oxaliplatin-based regimen. We have entered an era of chemo-diversity in the treatment of advanced HCC. This review aimed to clarify the relevance of HAIC in the era of chemo-diversity. We propose a multidisciplinary therapeutic strategy combining locoregional HAIC treatment with sequential drug therapy, with the aim of becoming cancer-free through conversion therapy.
Citations
Citations to this article as recorded by
Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies Henry Sutanto, Galih Januar Adytia, Elisa Elisa, Ummi Maimunah Cancer Pathogenesis and Therapy.2026; 4(1): 1. CrossRef
GLS1 inhibitor CB-839 inhibits the malignant progression of 5-FU resistant hepatoma cells by regulating glutamine metabolism Hao Wang, Xiao-yan Wang, Jian-bo Ji, Zong-xue Zheng, Peng-fei Shang, Xiu-li Guo Chemico-Biological Interactions.2026; 423: 111812. CrossRef
Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma with obstructive jaundice: A case report and review of literature Li Zhang, Pan Xiao, Lian-Dong Shi, Ke-Xin Chen, You-Fu Bing World Journal of Gastrointestinal Oncology.2026;[Epub] CrossRef
The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors Yi Fang, Bo Lao, Wenjia Fang Discover Oncology.2026;[Epub] CrossRef
Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Peng Jiang, Chao Chen, Jing Tian, Fan Yang, Zhen-yu Jiang, An-xiang Hu, Bin Liu Academic Radiology.2025; 32(8): 4595. CrossRef
Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way? Stefan Patauner, Giovanni Scotton, Francesca Notte, Antonio Frena World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion Shuangyan Tang, Feng Shi, Yi Xiao, Hongjie Cai, Ping Ma, Yuanmin Zhou, Zhiqiang Wu, Song Chen, Wenbo Guo Hepatology International.2025; 19(1): 106. CrossRef
Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma Huangpeng Lin, Zexian Ma, Jin Li, Heping Zhu, Xuefeng Huang, Huimin Chen, Liang Tu, Yifan Lian, Yongjie Su Frontiers in Immunology.2025;[Epub] CrossRef
Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis Wangyi Xuan, Xiaoming Zhang, Yingying Fang, Yueming Zhang, Zhiyi Xiang, Yifei Yu, Qingping Wu, Xingfen Zhang Oncology Letters.2025;[Epub] CrossRef
Anticipation for hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma Grigorios Christodoulidis, Dimitra Bartzi, Konstantinos E Koumarelas World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway Hua Xiao, Zhaoying Yao, Tao Li, Xin Fang, Xuejiao Xu, Sheng Hu, Ya Yang, Chenchen Jin, Yuxiang Fei, Chao Liu, Qianming Du International Immunopharmacology.2025; 150: 114259. CrossRef
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis Lingling Zhao, Cheng Xu, Jiewen Deng, Yang Ni Frontiers in Oncology.2025;[Epub] CrossRef
Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment Kristin E. Goodsell, Alice J. Tao, James O. Park Frontiers in Surgery.2025;[Epub] CrossRef
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review Ying Wu, Zhenpeng Zeng, Shuanggang Chen, Danyang Zhou, Gangling Tong, Duanming Du Frontiers in Immunology.2025;[Epub] CrossRef
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023 Qi-Feng Chen, Xiong-Ying Jiang, Min-Shan Chen, Ning Lyu, Ming Zhao Annals of Surgery Open.2025; 6(1): e562. CrossRef
Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching Qunfang Zhou, Hui Li, Ye Liang, Ruixia Li, Xiaohui Wang, Wei Wang, Mingyu Liu, Feng Duan, Zhimei Huang La radiologia medica.2025; 130(5): 662. CrossRef
Future perspectives on immunotherapy for hepatocellular carcinoma Landon L. Chan, Stephen L. Chan Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Novel multimodal analgesic regimen for perioperative pain management after hepatic artery infusion chemotherapy in patients with advanced hepatocellular carcinoma Jing Yan, Rui An, Jing-Jing Wang, Min Wang, Qi Zhao, Shen Zhao, Jian Xu World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study Yi Zhang, Ze Zhang, Xiaoxv Yin, Anhui Xu, Yonghong Hao, Nan Jiang, Ruibing Zhou, Ketao Mu European Radiology.2025; 35(10): 6564. CrossRef
A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma Xing-Yan Le, Jun-Bang Feng, Xiao-Li Yu, Sui-Li Li, Xiaocai Zhang, Jiaqing Li, Chuan-Ming Li BMC Gastroenterology.2025;[Epub] CrossRef
Natural born Killers: Harnessing NK cells to treat cancer Kanchi Patell, Katherine Myers, Amr Mohamed, David Wald, J. Eva Selfridge Best Practice & Research Clinical Haematology.2025; 38(3): 101630. CrossRef
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging Weihao Zhang, Xiaohui Zhao, Wei Gao, Tongguo Si, Qiang Zou, Xueling Yang, Wenge Xing, Haipeng Yu Frontiers in Immunology.2025;[Epub] CrossRef
Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491. CrossRef
Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning Fan Yao, Jianliang Miao, Bing Quan, Jinghuan Li, Bei Tang, Shenxin Lu, Xin Yin Journal of Hepatocellular Carcinoma.2025; Volume 12: 1111. CrossRef
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study Mao-Yuan Mu, Zi-Xiong Chen, Yu-Zhe Cao, Xiao-Bo Fu, Li-Jie Qiu, Han Qi, Fei Gao Cancer Letters.2025; 628: 217851. CrossRef
Comprehensive multi-omics analysis of bile acid metabolism in hepatocellular carcinoma: implications for prognosis, immune microenvironment, and therapeutic resistance Jiayan Ma, Ming Cheng, Limin Jin, Yong Wang, Zhengyang Feng, Yuntian Shen, Yaqun Zhu, Qiliang Peng Clinical and Translational Oncology.2025; 27(12): 4430. CrossRef
Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study Qiuhan Heng, Ying Leng, Gang Bai, Hua Yu Medicine.2025; 104(24): e42834. CrossRef
Combining Hepatic Arterial Interventional Therapies with Lenvatinib and Programmed Cell Death-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Single-Center, Real-World Study Xuehan Shen, Tianyin Shao, Jun Yu, Zhiwei Zhang Journal of Hepatocellular Carcinoma.2025; Volume 12: 1267. CrossRef
Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma Yangshuo Xia, Wu Wen, Yangyu Liao, Yingxiao Cai, Renhua Wan Journal of Hepatocellular Carcinoma.2025; Volume 12: 1425. CrossRef
Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma Hai Huang, Wang Peng, Qiaodan Zhou, Yuchong Zhao, Luyao Liu, Haochen Cui, Jingwen Liang, Mengdie Cao, Wei Chen, Ronghua Wang, Shiru Chen, Si Xiong, Bin Cheng, Shuya Bai Cell Communication and Signaling.2025;[Epub] CrossRef
Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study Jienan Lu, Lusha Zhou, Shuai Zhang, Junxiu Li, Tanrong Liu, Bingying Huang Journal of Surgical Oncology.2025; 132(5): 917. CrossRef
Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort Yangyang Ou, Yiyu Chen, Kang Chen, Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan The American Journal of Surgery.2025; 250: 116602. CrossRef
Efficacy of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma: a comparison with transarterial chemoembolization combined with TKIs Lei Fan, Lei Wang Acta Radiologica.2025; 66(12): 1311. CrossRef
Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma Shuirong Lin, Zimin Song, Peizhe Chen, Xi Yu, Wenxuan Xie, Yunpeng Hua, Shaoqiang Li, Shunli Shen, Ming Kuang Liver Cancer.2025; : 1. CrossRef
PARK7-driven IGF2BP3–K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma Zhiwen Zhu, Xinyu Xia, Yuanxiang Lu, Danfeng Li, Xincheng He, Baohua Zhang, Ge Xiong, Wanguang Zhang, Huifang Liang, Hong Zhu Redox Biology.2025; 87: 103869. CrossRef
FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level Yuan Li, Wenna Liu, Xushen Fan, Xinyi Wu, Mingbo Cao, Xiuling Li, Amin Wurita, Suofeng Sun Journal of Translational Medicine.2025;[Epub] CrossRef
The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma Tianyu Ma, Feilong Zhao, Linmei Yao, Chuanchun Mao, Yuan Tian, Youyou Ma, Fanyun Kong, Ruyu Liu Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (> 10 cm) with major portal vein tumor thrombosis: a multicenter propensity score matching analysis Yangyang Li, Danchen Wang, Fengtao Zhang, Xiang Zheng, Yipei Song, Yang Ran, Xiangran Cai Frontiers in Immunology.2025;[Epub] CrossRef
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma Yi-Min Zhang, Xin-Tong Wu, Jun-Zhe Yi, Jie Xu, Yu-Nan Zhang, Ning Lyu, Ming Zhao Liver Cancer.2025; 14(5): 620. CrossRef
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepato Zha Peng, Yaqiong Wang, Boyu Chen, Zhuangrong Zhu, Chengyi He, Yang Wei, Hai Huang Frontiers in Oncology.2025;[Epub] CrossRef
Consensus Integration of Multiomics Data With Machine Learning Algorithms Reveals Heterogeneous Molecular Subtypes and Enables Personalized Treatment Strategies for Hepatocellular Carcinoma Zhipeng Jin, Kun Fang, Xue Zhang, Mengying Song, Hong Jiang, Yefu Liu, Sujit Nair Human Mutation.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report Jiaxuan Liu, Zichun Zhao, Yulong Tian, Haibo Shao Discover Oncology.2025;[Epub] CrossRef
Conversion Therapy and Liver Regeneration in Liver Cancer Xiaoqin Wu Journal of Biosciences and Medicines.2025; 13(12): 374. CrossRef
Dual roles of USP1 in HELLS deubiquitination and SUMOylation drive EMT and FOLFOX-based chemoresistance Jie Gao, Nan Bai, Mingyu Liu, Ninghua Yao, Zhangzhi Tang, Banglong Xu, Weiting Chen, Xuyang He, Jiayu Shao, Saiyan Bian, Hui Zhao, Wenjie Zheng Oncogenesis.2025;[Epub] CrossRef
Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao Cancer Cell International.2024;[Epub] CrossRef
Efficacy and Safety of Hepatic Arterial Infusion Therapy with Cinobufacini in Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Retrospective Cohort Study Tao Xue, Hongbin Yu, Wenming Feng, Yao Wang, Shiyong Wu, Lili Wang, Peiqin Zhu, Jianming Guan, Quan Sun Cancer Management and Research.2024; Volume 16: 163. CrossRef
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities Ming‐Da Wang, Xue‐Jun Xu, Ke‐Chun Wang, Yong‐Kang Diao, Jia‐Hao Xu, Li‐Hui Gu, Lan‐Qing Yao, Chao Li, Guo‐Yue Lv, Tian Yang Cancer Science.2024; 115(7): 2159. CrossRef
Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Suho Kim, Jung Suk Oh, Ho Jong Chun, Pil Soo Sung Abdominal Radiology.2024; 49(9): 3127. CrossRef
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Gastro Hep Advances.2024; 3(4): 506. CrossRef
Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma Ji Kim, Young Kim, Hee-Chul Nam, Chang-Wook Kim, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Ho Jong Chun, Jung Oh, Suho Kim, Sung Lee, Pil Sung Oncology Letters.2024;[Epub] CrossRef
Combining liver-directed and immunotherapy in advanced hepatocellular carcinoma: A review and future directions Pranav Kumar, Chase J. Wehrle, Keyue Sun, Chunbao Jiao, Rebecca Panconesi, Mingyi Zhang, Noah X. Tocci, Hanna Hong, Abby Gross, Erlind Allkushi, Maureen Whitsett Linganna, Andrea Schlegel, Toms Augustin, Charles Miller, David CH Kwon, Kazunari Sasaki, Fed Surgical Oncology Insight.2024; 1(4): 100100. CrossRef
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy Eda Caliskan Yildirim, Yakup Ergun World Journal of Gastrointestinal Oncology.2024; 16(12): 4757. CrossRef
Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung Frontiers in Oncology.2024;[Epub] CrossRef
Bavachin stimulates ferroptosis and reduces malignant phenotype progression of hepatocellular carcinoma cells by inducing lipid peroxidation by modulation of the Nrf2/HO-1 signaling pathway Haoyu Li American Journal of Translational Research.2024; 16(11): 6925. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer Wenli Lin, Zhongxian Huang, Zhenhua Du, Yunshan Wang, Taiyang Zuo Frontiers in Oncology.2023;[Epub] CrossRef
Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab Matthew Ledenko, Lydia Mercado, Tushar Patel American Journal of Clinical Oncology.2024; 47(3): 105. CrossRef
Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma Etsuko Moriyama, Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, Masatoshi Tanaka, Tomotake Shirono, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Current Oncology.2024; 31(10): 5821. CrossRef
Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab” Binghua Li, Qiang Wang, Weiwei Hu, Huan Li, Peng Yan, Yajuan Cao, Decai Yu iLIVER.2024; 3(4): 100130. CrossRef
A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma Chih-Lang Lin, Kung-Hao Liang, Ching-Chih Hu, Cheng-Hung Chien, Li-Wei Chen, Rong-Nan Chien, Yang-Hsiang Lin, Chau-Ting Yeh International Journal of Molecular Sciences.2023; 24(2): 1681. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
Hepatocellular carcinoma (HCC) is usually accompanied by chronic liver damage, which sometimes influences the selection of HCC treatment. The Barcelona Clinic Liver Cancer (BCLC) staging system, which was first introduced in 1999, is the most commonly used worldwide. Although the intermediate-stage (BCLC stage B) includes the largest number and heterogeneous HCC patients, the recommended treatment option is transarterial chemoembolization (TACE) only. However, recent progress in radical treatments such as hepatic resection, liver transplantation, radiation therapy, and percutaneous therapy has made it possible to treat selected patients with BCLC stage B HCC. Radical treatments are expected to prolong survival time. To-date, TACE has also progressed. In addition to conventional TACE, balloon-occluded TACE and drug-eluting beads TACE are available. These new modalities of TACE will improve therapeutic efficacy and reduce adverse events. One of the most serious concerns of TACE is that repeated TACE reduces the treatment effect and induces liver function impairment. The decision on when TACE should be interrupted is complex. Many molecular targeted agents are now available, and immune checkpoint inhibitors will soon be available for HCC patients with Child-Pugh class A worldwide. Under these circumstances, in patients with TACE unsuitability, switching to molecular targeted agents before deterioration of liver function might improve the prognosis compared to repeated TACE. We should pay attention to stop TACE in TACE-unsuitable HCC patients as it can induce the deterioration of liver function.
Citations
Citations to this article as recorded by
MRI‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization Weilang Wang, Xiuming Zhang, Yixing Yu, Feng Feng, Wu Cai, Shuwei Zhou, Shuhang Zhang, Binrong Li, Tianyi Xia, Shenghong Ju, Yuan‐Cheng Wang Liver International.2026;[Epub] CrossRef
Prognostic significance of combined PCPE-1 and α-fetoprotein for hepatocellular carcinoma Ruhua Zhang, Wanqi Chen, Xuelan Peng, Zhiguang Zhang, Shangjiu Yang, Li Zhong Translational Oncology.2025; 51: 102185. CrossRef
Prediction of treatment response and outcome of transarterial chemoembolization in patients with hepatocellular carcinoma using artificial intelligence: A systematic review of efficacy Pedram Keshavarz, Nariman Nezami, Fereshteh Yazdanpanah, Maryam Khojaste-Sarakhsi, Zahra Mohammadigoldar, Mobin Azami, Azadeh Hajati, Faranak Ebrahimian Sadabad, Jason Chiang, Justin P. McWilliams, David S.K. Lu, Steven S. Raman European Journal of Radiology.2025; 184: 111948. CrossRef
Advanced targeted microsphere embolization for arteriovenous malformations: state-of-the-art and future directions Ali Mortezaei, Khaled M. Taghlabi, Nadir Al-Saidi, Saketh Amasa, Rachael E. Whitehead, Alex Hoang, Kurt Yaeger, Amir H. Faraji, Ramanathan Kadirvel, Sherief Ghozy Neuroradiology.2025; 67(4): 1009. CrossRef
Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study Ga Ram You, Shin Young Park, Su Hyeon Cho, Sung Bum Cho, Yang Seok Koh, Chang Hun Lee, Hoon Gil Jo, Sung Kyu Choi, Jae Hyun Yoon Cancers.2025; 17(9): 1417. CrossRef
Exosomal miRNA-720 as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma Ji Min Kim, Hye Seon Kim, Jin Seoub Kim, Ji Won Han, Soon Kyu Lee, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang The Korean Journal of Internal Medicine.2025; 40(6): 939. CrossRef
Outcomes of robotic liver resection and intraoperative radiofrequency ablation for hepatocellular carcinoma in posterior segments VII and VIII Cheng-Ming Peng, Shao-Chieh Lin, Yung-Yin Cheng, Teng-Chieh Cheng, Ching-Lung Hsieh, Chia-Hong Hsieh, Mei-Fang Hsieh, Chun-Han Liao, Ming-Cheng Liu, Yi-Jui Liu World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park Gut and Liver.2024; 18(1): 116. CrossRef
Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma Han Ah Lee, Minjong Lee, Jeong-Ju Yoo, Ho Soo Chun, Yewan Park, Hwi Young Kim, Tae Hun Kim, Yeon Seok Seo, Dong Hyun Sinn International Journal of Surgery.2024; 110(2): 1008. CrossRef
A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization Hae Lim Lee, Seok Hwan Kim, Hee Yeon Kim, Sung Won Lee, Myeong Jun Song Frontiers in Oncology.2024;[Epub] CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma Ji Kim, Young Kim, Hee-Chul Nam, Chang-Wook Kim, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Ho Jong Chun, Jung Oh, Suho Kim, Sung Lee, Pil Sung Oncology Letters.2024;[Epub] CrossRef
Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi Journal of Liver Cancer.2024; 24(2): 274. CrossRef
Percutaneous radiofrequency ablation for stage B1 of modified Bolondi’s subclassification for intermediate-stage hepatocellular carcinoma Ragaey Ahmad Eid, Ali M. Abdel Fattah, Alaa Farouk Haseeb, Ahmed Moheyeldien Hamed, Marwa Abdallah Shaker Egyptian Liver Journal.2024;[Epub] CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2023; 107: 66. CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Barriers to palliative care in hepatocellular carcinoma: A review of the literature Mostafa Abasseri, Shakira Hoque, BA Slavica Kochovska, Kim Caldwell, Linda Sheahan, Amany Zekry Journal of Gastroenterology and Hepatology.2023; 38(7): 1047. CrossRef
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maj Cancer Treatment Reviews.2023; 115: 102526. CrossRef
Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung Frontiers in Oncology.2023;[Epub] CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao Clinical and Molecular Hepatology.2023; 29(2): 206. CrossRef
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation Carlo Bosi, Margherita Rimini, andrea Casadei-Gardini, Giorgio Ercolani Expert Review of Anticancer Therapy.2023; 23(5): 503. CrossRef
The clinical management of hepatocellular carcinoma in China: Progress and challenges Shan Shan, Jidong Jia Clinical and Molecular Hepatology.2023; 29(2): 339. CrossRef
Establishment and application of a survival rate graph model based on biomarkers and imaging indexes after primary hepatocellular carcinoma resection Yue Xu, Xiaoqin Yao, Jinmei Li, Guoyuan Zhang, Guangcheng Luo, Qiang Wang Cancer Medicine.2023; 12(12): 13329. CrossRef
Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis Jiaye Long, Baoxiang Chen, Zhaohui Liu Frontiers in Oncology.2023;[Epub] CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim Clinical and Molecular Hepatology.2023; 29(3): 763. CrossRef
Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu Medicine.2023; 102(32): e34637. CrossRef
Efficacy and safety of CalliSpheres® Microsphere transcatheter-arterial chemoembolization versus conventional TACE in treating renal angiomyolipoma patients Tianshi Lyu, Jian Wang, Xiaoqiang Tong, Tianai Mi, Chao An, Yinghua Zou Journal of Cancer Research and Therapeutics.2023; 19(4): 933. CrossRef
Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management Jessica Elderkin, Najeeb Al Hallak, Asfar S. Azmi, Hussein Aoun, Jeffrey Critchfield, Miguel Tobon, Eliza W. Beal Cancers.2023; 15(21): 5118. CrossRef
Polyamines: their significance for maintaining health and contributing to diseases Mengjuan Xuan, Xinyu Gu, Juan Li, Di Huang, Chen Xue, Yuting He Cell Communication and Signaling.2023;[Epub] CrossRef
Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors Hideki Iwamoto, Satoshi Itano, Osamu Itano, Masatsugu Ishii, Takashi Niizeki, Tomotake Shirono, Shigeo Shimose, Hiroyuki Suzuki, Akira Kajiwara, Taizo Yamaguchi, Hironori Koga, Takuji Torimura Japanese Journal of Radiology.2022; 40(3): 326. CrossRef
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon Cancers.2022; 14(7): 1747. CrossRef
Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Moonhwan Kim, Yeongsoo Jo HPB.2022; 24(9): 1569. CrossRef
Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus? Won Hyeok Choe Journal of Liver Cancer.2022; 22(1): 1. CrossRef
Association between achieving textbook outcomes and better survival after laparoscopic liver resection in the anterolateral segments in patients with hepatocellular carcinoma Mizelle D'Silva, Jai Young Cho, Ho‐Seong Han, Yoo‐Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim, Yeongsoo Jo Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(8): 855. CrossRef
A Case-Matched Analysis of Laparoscopic Liver Resection for Hepatocellular Carcinoma Located in Posterosuperior Segments of the Liver According to Adaption of Developed Techniques Yujin Kwon, Boram Lee, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Munwhan Kim, Youngsoo Jo Medicina.2022; 58(4): 543. CrossRef
Long-Term Outcomes of Laparoscopic Liver Resection for Centrally Located Hepatocellular Carcinoma Hyo Jun Kim, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Yeongsoo Jo, Meeyouong Kang, Yeshong Park, Eunhye Lee Medicina.2022; 58(6): 737. CrossRef
Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis Man Yao, Simo Cheng, Xiaofeng Zhai, Hetong Zhao, Jing Hong, Xiaoyan Li, Yongbin Meng, Wei Chen, Ye Liu Applied Bionics and Biomechanics.2022; 2022: 1. CrossRef
Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim Cancers.2022; 14(20): 5002. CrossRef
Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study Jae Hyun Yoon, Sung Kyu Choi, Sung Bum Cho, Hee Joon Kim, Yang Seok Ko, Chung Hwan Jun World Journal of Gastroenterology.2022; 28(36): 5351. CrossRef
Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study Dashuai Yang, Yang Su, Fangrui Zhao, Yong Hu, Kailiang Zhao, Xiangyun Xiong, Mingqiang Zhu, Junpeng Pei, Youming Ding Expert Review of Gastroenterology & Hepatology.2022; 16(11-12): 1115. CrossRef
The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment Janett Fischer, Stella Wellhöner, Sebastian Ebel, Thomas Lincke, Albrecht Böhlig, Florian Gerhardt, Rhea Veelken, Holger Goessmann, Karen Geva Steinhoff, Timm Denecke, Osama Sabri, Thomas Berg, Florian van Bömmel Cancers.2022; 14(21): 5323. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older Jong Man Kim, Jinsoo Rhu, Sang Yun Ha, Gyu-Seong Choi, Choon Hyuck David Kwon, Gaabsoo Kim, Jae-Won Joh Annals of Surgical Treatment and Research.2021; 101(5): 257. CrossRef
Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Cancers.2021; 14(1): 67. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Sung Kyu Hwang, Young Eun Chon, Hong Jae Chon SSRN Electronic Journal .2021;[Epub] CrossRef
First
Prev
